医薬品製剤市場：剤形、技術、治療領域、エンドユーザー別-2024-2030年の世界予測

医薬品製剤市場規模は2023年に2兆4,200億米ドルと推計され、2024年には2兆5,500億米ドルに達し、CAGR 5.70%で2030年には3兆5,600億米ドルに達すると予測されています。

医薬品製剤は、医薬品有効成分（API）が他の物質と組み合わされ、患者にとって安全で有効かつ利便性の高い最終的な医薬品が作られるプロセスを指します。この技術的かつ複雑なプロセスには、人体内でのAPIの安定性、生物学的利用能、最適な性能を確保するために適切な賦形剤を選択することが含まれます。慢性疾患の蔓延、ドラッグデリバリー技術の進歩、個別化医療の進展により、より多くの医薬品製剤の必要性が高まっています。膨大な可能性があるにもかかわらず、医薬品製剤は、開発コストの高さ、規制上のハードル、安定性が高く味や投与方法が患者に受け入れられる製剤を作ることの複雑さといった課題に直面しています。これらの制約に対処するには、研究開発への継続的な投資、革新的技術の採用、規制戦略の適応性と効率性の確保が必要です。ナノテクノロジー、徐放性製剤、生分解性ポリマーなどの新規ドラッグデリバリーシステムの探求は、薬剤の有効性と患者のコンプライアンスをさらに高め、医薬品医療の状況を一変させる可能性があると期待されています。

剤形：慢性治療における経口製剤の利便性と有効性

吸入製剤は呼吸器に直接投与するように設計されています。主に喘息や慢性閉塞性肺疾患（COPD）など、肺に影響を及ぼす疾患に使用されます。この製剤は作用発現が早く、全身的な副作用が少ないです。速やかな緩和や管理が必要な肺疾患には、この方法が好まれます。錠剤、カプセル剤、液剤などの経口剤は、最も一般的な薬物投与形態です。これらの製剤は消化管（GI）を通して全身に吸収されるように設計されており、投与が容易で患者のコンプライアンスも高いことから、慢性疾患に広く好まれています。非経口製剤は消化管をバイパスして投与され、主に静脈内、筋肉内、皮下ルートから投与されます。非経口製剤は、迅速な吸収が必要な治療や、消化管からの吸収が悪い薬剤の投与に不可欠です。緊急用医薬品、生物製剤、薬物のバイオアベイラビリティを正確にコントロールする必要がある治療には不可欠です。外用剤には、皮膚表面に塗布するクリーム、軟膏、ゲル、パッチなどがあります。これらは主に局所的な治療に使用され、全身への曝露を最小限に抑えられるという利点があります。局所ドラッグデリバリーによる皮膚疾患や疼痛管理に最適です。

エンドユーザー：製薬会社による医薬品開発への投資の増加

学術研究機関は主に、革新的な製剤やドラッグデリバリーシステムの開発に注力しています。また、潜在的な治療効果を持つ新規化合物の探索も頻繁に行われています。医薬品開発・製造受託機関（CDMO）は、医薬品開発から製造まで幅広いサービスを提供し、医薬品製剤分野で極めて重要な役割を担っています。CDMOは、柔軟性、拡張性、市場投入までのスピードに重点を置き、コアコンピタンスに集中するためにこれらの面をアウトソースすることを目的とする製薬会社に対応しています。病院や診療所は、医薬品の投与を通じて患者の治療に専念する主要なエンドユーザーです。彼らが好むのは、安全で効果が高く、患者のコンプライアンスを向上させる医薬品です。このセクターは、投与レジメを簡素化し、治療成果を高めることができる製剤に特に関心を寄せています。製薬会社は医薬品製剤産業の中心的存在であり、医薬品の発見、開発、生産、販売に従事しています。

地域別の洞察

南北アメリカ、特に米国では、大手製薬会社が存在し、FDAを中心とした規制の枠組みが確立されているため、革新的な医薬品製剤技術が重視されています。そのため、生物製剤や徐放性製剤などの複雑な製剤を中心とした研究開発（R&D）への投資が活発に行われています。また、南北アメリカの生産能力は先進的な製造設備によって強化されており、新製剤の迅速なスケーラビリティを可能にしています。APACは、医療費の増加、ジェネリック医薬品の需要拡大、規制枠組みの改善などを背景に、医薬品製剤市場の主要プレーヤーとして急速に台頭しています。インドや中国のような国々は、費用対効果の高い製造と多くの科学的人材を活用し、ジェネリック医薬品の生産をリードしています。EMEA地域は、特に欧州連合（EU）諸国において、高品質医薬品製剤と厳格な規制基準に強く焦点を当てた成熟市場です。EMEA地域の非公開会社は、先進的なドラッグデリバリーシステムと個別化医療をリードしており、強固なヘルスケアシステムと医薬品研究開発への政府および民間からの多額の投資に支えられています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、医薬品製剤市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、医薬品製剤市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.医薬品製剤市場の市場規模および予測は？

2.医薬品製剤市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.医薬品製剤市場の技術動向と規制枠組みは？

4.医薬品製剤市場における主要ベンダーの市場シェアは？

5.医薬品製剤市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の蔓延と効果的な治療の必要性
    • 医薬品の開発と発見を奨励する政府の取り組み
    • パーソナライズされた医療と治療法の台頭
  • 抑制要因
    • 医薬品の有害事象による回収
  • 機会
    • ドラッグデリバリーおよび投薬技術の進歩
    • ジェネリック医薬品開発のためのCDMOへの投資
  • 課題
    • 医薬品製剤の複雑な開発と処理
• 市場セグメンテーション分析
  • 剤形：慢性治療における経口剤の利便性と有効性
  • エンドユーザー：製薬会社による医薬品開発への投資増加
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 医薬品製剤市場剤形別

• 吸入製剤
• 経口製剤
• 非経口製剤
• 局所用製剤

第7章 医薬品製剤市場：技術別

• 即効性製剤
• リポソーム製剤
• マイクロスフィア製剤
• 放出調節製剤
• ナノ製剤
• 自己乳化型ドラッグデリバリーシステム
• 固体分散製剤

第8章 医薬品製剤市場治療領域別

• 心臓血管
• 中枢神経系
• 皮膚科
• 内分泌学
• 胃腸
• 免疫学
• 感染症
• 腫瘍学
• 眼科
• 疼痛管理
• 呼吸器

第9章 医薬品製剤市場：エンドユーザー別

• 学術・調査機関
• 契約開発および製造組織
• 病院・クリニック
• 製薬会社

第10章 南北アメリカの医薬品製剤市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の医薬品製剤市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの医薬品製剤市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • グレンマーク、インドの2型糖尿病患者向けにトリプル医薬品製剤を開始
  • ニューロクライン・バイオサイエンス社、米国FDAがINGREZZA（バルベナジン）経口顆粒スプリンクル製剤の新薬申請を受理したことを発表
  • メルクとXtalPiのコラボレーションにより、AIを活用した技術で医薬品の処方を最適化
• 戦略分析と提言

第14章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. DRUG FORMULATION MARKET RESEARCH PROCESS
• FIGURE 2. DRUG FORMULATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. DRUG FORMULATION MARKET DYNAMICS
• FIGURE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. DRUG FORMULATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. DRUG FORMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DRUG FORMULATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL DRUG FORMULATION MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRESSURIZED METERED DOSE INHALER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRESSURIZED METERED DOSE INHALER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL DRUG FORMULATION MARKET SIZE, BY GUMMIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL DRUG FORMULATION MARKET SIZE, BY GUMMIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL DRUG FORMULATION MARKET SIZE, BY LOZENGES & PASTILLES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL DRUG FORMULATION MARKET SIZE, BY LOZENGES & PASTILLES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS & GRANULES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS & GRANULES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLETS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLETS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL DRUG FORMULATION MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL DRUG FORMULATION MARKET SIZE, BY EMULSIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAMS, LOTIONS, & FOAMS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAMS, LOTIONS, & FOAMS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, TINCTURES, & POWDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, TINCTURES, & POWDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENTS & OILS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENTS & OILS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL DRUG FORMULATION MARKET SIZE, BY PASTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL DRUG FORMULATION MARKET SIZE, BY PASTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPRAYS & PATCHES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPRAYS & PATCHES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMEDIATE-RELEASE FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMEDIATE-RELEASE FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 67. GLOBAL DRUG FORMULATION MARKET SIZE, BY MICROSPHERE FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 68. GLOBAL DRUG FORMULATION MARKET SIZE, BY MICROSPHERE FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 69. GLOBAL DRUG FORMULATION MARKET SIZE, BY MODIFIED-RELEASE FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 70. GLOBAL DRUG FORMULATION MARKET SIZE, BY MODIFIED-RELEASE FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 71. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOFORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 72. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOFORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 73. GLOBAL DRUG FORMULATION MARKET SIZE, BY SELF-EMULSIFYING DRUG DELIVERY SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 74. GLOBAL DRUG FORMULATION MARKET SIZE, BY SELF-EMULSIFYING DRUG DELIVERY SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 75. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID DISPERSION FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 76. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID DISPERSION FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 77. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 78. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 79. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 80. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 81. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2023 (USD MILLION)
• TABLE 82. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2024-2030 (USD MILLION)
• TABLE 83. GLOBAL DRUG FORMULATION MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 84. GLOBAL DRUG FORMULATION MARKET SIZE, BY DERMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 85. GLOBAL DRUG FORMULATION MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 86. GLOBAL DRUG FORMULATION MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 87. GLOBAL DRUG FORMULATION MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 88. GLOBAL DRUG FORMULATION MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 89. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 90. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 91. GLOBAL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 92. GLOBAL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 93. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 94. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 95. GLOBAL DRUG FORMULATION MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 96. GLOBAL DRUG FORMULATION MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 97. GLOBAL DRUG FORMULATION MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 98. GLOBAL DRUG FORMULATION MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 99. GLOBAL DRUG FORMULATION MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 100. GLOBAL DRUG FORMULATION MARKET SIZE, BY RESPIRATORY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 101. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 102. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 103. GLOBAL DRUG FORMULATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 104. GLOBAL DRUG FORMULATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 105. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 106. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 107. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 108. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 109. GLOBAL DRUG FORMULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 110. GLOBAL DRUG FORMULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 111. AMERICAS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 112. AMERICAS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 113. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 114. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 115. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 116. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 117. AMERICAS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 118. AMERICAS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 119. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 120. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 121. AMERICAS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 122. AMERICAS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 123. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 124. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 125. AMERICAS DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 126. AMERICAS DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 127. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 128. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 129. ARGENTINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 130. ARGENTINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 131. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 132. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 133. ARGENTINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 134. ARGENTINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 135. ARGENTINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 136. ARGENTINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 137. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 138. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 139. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 140. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 141. ARGENTINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 142. ARGENTINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 143. ARGENTINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 144. ARGENTINA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 145. BRAZIL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 146. BRAZIL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 147. BRAZIL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 148. BRAZIL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 149. BRAZIL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 150. BRAZIL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 151. BRAZIL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 152. BRAZIL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 153. BRAZIL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 154. BRAZIL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 155. BRAZIL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 156. BRAZIL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 157. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 158. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 159. BRAZIL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 160. BRAZIL DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 161. CANADA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 162. CANADA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 163. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 164. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 165. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 166. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 167. CANADA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 168. CANADA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 169. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 170. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 171. CANADA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 172. CANADA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 173. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 174. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 175. CANADA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 176. CANADA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 177. MEXICO DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 178. MEXICO DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 179. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 180. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 181. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 182. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 183. MEXICO DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 184. MEXICO DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 185. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 186. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 187. MEXICO DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 188. MEXICO DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 189. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 190. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 191. MEXICO DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 192. MEXICO DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 193. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 194. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 195. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 196. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 197. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 198. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 199. UNITED STATES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 200. UNITED STATES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 201. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 202. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 203. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 204. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 205. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 206. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 207. UNITED STATES DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 208. UNITED STATES DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 209. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 210. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 211. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 212. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 213. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 214. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 215. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 216. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 217. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 218. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 219. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 220. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 221. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 222. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 223. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 224. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 225. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 226. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 227. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 228. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 229. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 230. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 231. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 232. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 233. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 234. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 235. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 236. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 237. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 238. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 239. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 240. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 241. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 242. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 243. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 244. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 245. CHINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 246. CHINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 247. CHINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 248. CHINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 249. CHINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 250. CHINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 251. CHINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 252. CHINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 253. CHINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 254. CHINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 255. CHINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 256. CHINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 257. CHINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 258. CHINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 259. CHINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 260. CHINA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 261. INDIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 262. INDIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 263. INDIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 264. INDIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 265. INDIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 266. INDIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 267. INDIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 268. INDIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 269. INDIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 270. INDIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 271. INDIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 272. INDIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 273. INDIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 274. INDIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 275. INDIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 276. INDIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 277. INDONESIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 278. INDONESIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 279. INDONESIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 280. INDONESIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 281. INDONESIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 282. INDONESIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 283. INDONESIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 284. INDONESIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 285. INDONESIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 286. INDONESIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 287. INDONESIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 288. INDONESIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 289. INDONESIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 290. INDONESIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 291. INDONESIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 292. INDONESIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 293. JAPAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 294. JAPAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 295. JAPAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 296. JAPAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 297. JAPAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 298. JAPAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 299. JAPAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 300. JAPAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 301. JAPAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 302. JAPAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 303. JAPAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 304. JAPAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 305. JAPAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 306. JAPAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 307. JAPAN DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 308. JAPAN DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 309. MALAYSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 310. MALAYSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 311. MALAYSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 312. MALAYSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 313. MALAYSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 314. MALAYSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 315. MALAYSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 316. MALAYSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 317. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 318. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 319. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 320. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 321. MALAYSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 322. MALAYSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 323. MALAYSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 324. MALAYSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 325. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 326. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 327. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 328. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 329. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 330. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 331. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 332. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 333. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
• TABLE 334. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
• TABLE 335. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 336. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 337. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 338. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILL

[193 Pages Report] The Drug Formulation Market size was estimated at USD 2.42 trillion in 2023 and expected to reach USD 2.55 trillion in 2024, at a CAGR 5.70% to reach USD 3.56 trillion by 2030.

Drug formulation refers to the process through which active pharmaceutical ingredients (APIs) are combined with other substances to create a final medicinal product that is safe, effective, and convenient for patients to use. This technical and intricate process involves choosing suitable excipients to ensure the stability, bioavailability, and optimal performance of the API in the human body. The prevalence of chronic diseases, advancements in drug delivery technologies, and the escalation of personalized medicine have been elevating the need for more drug formulations. Despite the immense potential, drug formulation faces challenges such as the high cost of development, regulatory hurdles, and the complexity of creating formulations that are both stable and acceptable to patients in terms of taste and administration method. Addressing these restraints requires continuous investment in R&D, adopting innovative technologies, and ensuring regulatory strategies are adaptable and efficient. The exploration of novel drug delivery systems such as nanotechnology, sustained-release formulations, and biodegradable polymers is expected to further enhance drug efficacy and patient compliance, potentially transforming the landscape of pharmaceutical care.

Dosage Form: Convenience and effectiveness of oral formulations for chronic treatments

Inhalation formulations are designed for direct delivery to the respiratory tract. They are primarily used for conditions affecting the lungs, such as asthma and chronic obstructive pulmonary disease (COPD). This delivery method offers rapid onset of action and reduced systemic side effects. It is preferred for pulmonary conditions requiring fast relief or management. Oral formulations, including tablets, capsules, and liquids, are the most common form of drug administration. They are designed for systemic absorption through the gastrointestinal (GI) tract and were widely preferred for chronic diseases due to ease of administration and patient compliance. Parenteral formulations are administered bypassing the GI tract, mainly through intravenous, intramuscular, and subcutaneous routes. They are critical for treatments that require rapid absorption or when the drug is poorly absorbed from the gut. It is essential for emergency medicines, biologics, and treatments requiring precise control over drug bioavailability. Topical formulations include creams, ointments, gels, and patches applied to the skin's surface. They are primarily used for localized treatment, offering the advantage of minimizing systemic exposure. It is ideal for dermatological conditions and pain management through localized drug delivery.

End User: Rising investments in drug developments by pharmaceutical companies

Academic and research institutions primarily focus on developing innovative formulations and drug delivery systems. They often explore novel compounds with potential therapeutic benefits. Contract development & manufacturing organizations (CDMOs) are pivotal in the drug formulation sector, providing a wide range of services from drug development to manufacturing. They focus on flexibility, scalability, and speed-to-market, catering to pharmaceutical companies that aim to outsource these aspects to focus on their core competencies. Hospitals and clinics are the primary end users focusing on patient care through the administration of drugs. Their preference leans towards pharmaceuticals that are safe, effective, and offer better patient compliance. This sector is particularly interested in formulations that can simplify dosing regimes and enhance therapeutic outcomes. Pharmaceutical companies are central to the drug formulation industry, engaged in the discovery, development, production, and marketing of medications.

Regional Insights

In the Americas, especially the United States, there is a significant emphasis on innovative drug formulation technologies due to the presence of major pharmaceutical companies and a well-established regulatory framework led by the FDA. This promotes a high level of investment in research and development (R&D), focusing on complex formulations such as biologics and sustained-release drugs. The production capacity in the Americas is also bolstered by advanced manufacturing facilities, enabling rapid scalability of new formulations. APAC is rapidly emerging as a key player in the drug formulation market, driven by increasing healthcare expenditure, growing demand for generic medicines, and improvements in regulatory frameworks. Countries like India and China are leading in the production of generics, leveraging cost-effective manufacturing and a large pool of scientific talent. The EMEA region presents a mature market with a strong focus on high-quality drug formulations and stringent regulatory standards, especially in the European Union (EU) countries. Companies in the EMEA region are leading in advanced drug delivery systems and personalized medicine, supported by robust healthcare systems and significant government and private investment in pharmaceutical R&D.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Drug Formulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Drug Formulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Drug Formulation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AbbVie Inc., Amgen, Inc., AstraZeneca plc., Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Catalent, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gerresheimer AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Marksans Pharma Ltd., Medicef Pharma, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd., and The Bristol-Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Drug Formulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Dosage Form
  • Inhalation Formulations
    • Dry Powder Inhaler
    • Nebulizer
    • Pressurized Metered Dose Inhaler

• Oral Formulations
  • Capsules
  • Gummies
  • Lozenges & Pastilles
  • Powders & Granules
  • Tablets

• Parenteral Formulations
  • Emulsions
  • Gels
  • Powders
  • Solutions
  • Suspensions

• Topical Formulations
  • Creams, Lotions, & Foams
  • Gels, Tinctures, & Powders
  • Ointments & Oils
  • Pastes
  • Sprays & Patches
• Technology
  • Immediate-Release Formulations
  • Liposomal Formulations
  • Microsphere Formulations
  • Modified-Release Formulations
  • Nanoformulations
  • Self-Emulsifying Drug Delivery Systems
  • Solid Dispersion Formulations

• Therapeutic Area
  • Cardiovascular
  • Central Nervous System
  • Dermatology
  • Endocrinology
  • Gastrointestinal
  • Immunology
  • Infectious Diseases
  • Oncology
  • Ophthalmology
  • Pain Management
  • Respiratory

• End User
  • Academic & Research Institutions
  • Contract Development & Manufacturing Organizations
  • Hospitals & Clinics
  • Pharmaceutical Companies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Drug Formulation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Drug Formulation Market?

3. What are the technology trends and regulatory frameworks in the Drug Formulation Market?

4. What is the market share of the leading vendors in the Drug Formulation Market?

5. Which modes and strategic moves are suitable for entering the Drug Formulation Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic diseases and need for effective treatments
    • 5.1.1.2. Government initiatives encouraging drug development and discovery
    • 5.1.1.3. Rise of personalized and tailored medicine and therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse recalls of drugs and medications
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in drug delivery and dosage technologies
    • 5.1.3.2. Investments in CDMOs to develop generic drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Complex development and processing of drug formulations
• 5.2. Market Segmentation Analysis
  • 5.2.1. Dosage Form: Convenience and effectiveness of oral formulations for chronic treatments
  • 5.2.2. End User: Rising investments in drug developments by pharmaceutical companies
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Drug Formulation Market, by Dosage Form

• 6.1. Introduction
• 6.2. Inhalation Formulations
• 6.3. Oral Formulations
• 6.4. Parenteral Formulations
• 6.5. Topical Formulations

7. Drug Formulation Market, by Technology

• 7.1. Introduction
• 7.2. Immediate-Release Formulations
• 7.3. Liposomal Formulations
• 7.4. Microsphere Formulations
• 7.5. Modified-Release Formulations
• 7.6. Nanoformulations
• 7.7. Self-Emulsifying Drug Delivery Systems
• 7.8. Solid Dispersion Formulations

8. Drug Formulation Market, by Therapeutic Area

• 8.1. Introduction
• 8.2. Cardiovascular
• 8.3. Central Nervous System
• 8.4. Dermatology
• 8.5. Endocrinology
• 8.6. Gastrointestinal
• 8.7. Immunology
• 8.8. Infectious Diseases
• 8.9. Oncology
• 8.10. Ophthalmology
• 8.11. Pain Management
• 8.12. Respiratory

9. Drug Formulation Market, by End User

• 9.1. Introduction
• 9.2. Academic & Research Institutions
• 9.3. Contract Development & Manufacturing Organizations
• 9.4. Hospitals & Clinics
• 9.5. Pharmaceutical Companies

10. Americas Drug Formulation Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Drug Formulation Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Drug Formulation Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Glenmark Launches Triple Drug Formulation for Type 2 Diabetes Patients in India
  • 13.3.2. Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA (valbenazine) Oral Granules Sprinkle Formulation
  • 13.3.3. Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques
• 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio